DK1583830T3 - Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner - Google Patents

Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner

Info

Publication number
DK1583830T3
DK1583830T3 DK04700438T DK04700438T DK1583830T3 DK 1583830 T3 DK1583830 T3 DK 1583830T3 DK 04700438 T DK04700438 T DK 04700438T DK 04700438 T DK04700438 T DK 04700438T DK 1583830 T3 DK1583830 T3 DK 1583830T3
Authority
DK
Denmark
Prior art keywords
cells
collection
library
nucleic acid
recombinant polyclonal
Prior art date
Application number
DK04700438T
Other languages
Danish (da)
English (en)
Inventor
John S Haurum
Finn C Wiberg
Jacqueline Sharon
Chiou-Ying Yang
Vincent W Coljee
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Application granted granted Critical
Publication of DK1583830T3 publication Critical patent/DK1583830T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
DK04700438T 2003-01-07 2004-01-07 Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner DK1583830T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43840303P 2003-01-07 2003-01-07
DKPA200300008 2003-01-07
US47601803P 2003-06-05 2003-06-05
PCT/DK2004/000001 WO2004061104A2 (en) 2003-01-07 2004-01-07 Method for manufacturing recombinant polyclonal proteins

Publications (1)

Publication Number Publication Date
DK1583830T3 true DK1583830T3 (da) 2007-01-15

Family

ID=32718469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04700438T DK1583830T3 (da) 2003-01-07 2004-01-07 Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner

Country Status (18)

Country Link
US (1) US9163232B2 (https=)
EP (2) EP1762617A1 (https=)
JP (2) JP4589914B2 (https=)
KR (1) KR101024443B1 (https=)
AT (1) ATE338816T1 (https=)
AU (1) AU2004203727C1 (https=)
BR (1) BRPI0406678A (https=)
CA (1) CA2512647C (https=)
DE (1) DE602004002275T2 (https=)
DK (1) DK1583830T3 (https=)
EA (1) EA013225B1 (https=)
ES (1) ES2273202T3 (https=)
IL (1) IL169101A (https=)
MX (1) MXPA05006724A (https=)
NZ (1) NZ541458A (https=)
PT (1) PT1583830E (https=)
SI (1) SI1583830T1 (https=)
WO (1) WO2004061104A2 (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8288109B2 (en) * 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EA014182B1 (ru) * 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
AU2006261909B2 (en) * 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
DK2121920T3 (da) 2007-03-01 2011-11-21 Symphogen As Fremgangsmåde til kloning af sammenhørende antistoffer
JP2010534057A (ja) 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
BRPI0818437B8 (pt) 2007-10-11 2021-05-25 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
NZ588651A (en) * 2008-04-23 2012-04-27 Symphogen As Methods for manufacturing a polyclonal protein
CN102137928A (zh) * 2008-08-29 2011-07-27 西福根有限公司 克隆禽源抗体的方法
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
PL2488202T3 (pl) 2009-10-15 2015-12-31 Avaxia Biologics Inc Przeciwciała terapeutyczne o aktywności miejscowej w przewodzie pokarmowym
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
WO2012068317A2 (en) 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
ES2791758T3 (es) 2011-12-22 2020-11-05 Hoffmann La Roche Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
BR112014024267A8 (pt) 2012-03-30 2017-07-25 Daiichi Sankyo Co Ltd anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada
MX2014011828A (es) 2012-03-30 2014-12-10 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2013160879A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4-antibody
WO2013164689A2 (en) 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
JP2015163047A (ja) * 2012-06-20 2015-09-10 国立大学法人 東京大学 タンパク質の迅速改良法
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
TWI664977B (zh) 2013-10-08 2019-07-11 第一三共股份有限公司 抗ｆｇｆｒ２抗體及其與其他藥劑之組合
WO2015093925A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Isaac Método de producción de anticuerpos específicos
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
WO2016197064A1 (en) 2015-06-04 2016-12-08 Epstein Alan L Lym-1 and lym-2 targeted car cell immunotherapy
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
EP3569244A1 (en) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
DK3354729T5 (da) 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
JP7202185B2 (ja) 2016-12-22 2023-01-11 第一三共株式会社 抗ｃｄ３抗体及び該抗体を含む分子
SG11201907321TA (en) 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
UA129904C2 (uk) 2017-04-05 2025-09-10 Ле Лаборатуар Сервьє Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
WO2019004487A1 (ja) 2017-06-30 2019-01-03 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
US11661451B2 (en) 2017-07-27 2023-05-30 Daiichi Sankyo Company, Limited Anti-CD147 antibody
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
EP3693012A4 (en) 2017-10-05 2021-07-21 Daiichi Sankyo Company, Limited CYTOTOXIC T-CELL DEPLOYMENT COMPOSITION
IL275239B2 (en) 2017-12-11 2026-03-01 Abalone Bio Inc Yeast presentation of proteins in the subplasmic space
MX2020008582A (es) 2018-03-05 2020-09-21 Univ Saitama Medical Composicion farmaceutica para tratar o prevenir la osificacion heterotopica.
BR112020021266A2 (pt) 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano
EP3810649A1 (en) * 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
SG11202012338QA (en) 2018-07-10 2021-01-28 Univ Kobe Nat Univ Corp ANTI-SIRPa ANTIBODY
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
WO2020084034A1 (en) * 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN113728003A (zh) 2019-04-30 2021-11-30 吉加根公司 重组多克隆蛋白及其使用方法
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
US20240190961A1 (en) 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
EP4084824A1 (en) 2019-12-31 2022-11-09 Antagonis Compositions and methods for the prevention of s. aureus infection
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) * 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
EP4204005A1 (en) 2020-08-31 2023-07-05 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155114A (en) * 1874-09-15 Improvement in methods of laying and forming cast-iron pipes
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
EP0530216A4 (en) 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
DE69534347T2 (de) * 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
AU737155B2 (en) * 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US20020155114A1 (en) 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU781628B2 (en) 1999-07-14 2005-06-02 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
DK1234022T3 (da) 1999-07-23 2010-07-19 Univ California DNA-rekombination i eukaryote celler med bakteriofag PHIC31-rekombinationssystemet
HK1052305B (en) * 2000-05-26 2007-10-12 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
EP1293564A4 (en) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp EXPRESSION VECTOR FOR SCREENING CELLS HIGH EXPRESSION OF RECOMBINANT PROTEINS, TRANSFORMING HIGH EXPRESSION OF A RECOMBINANT PROTEIN AND USE THEREOF
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
JP2004514444A (ja) * 2000-11-28 2004-05-20 アプライド　モレキュラー　エボリューション，　インコーポレイテッド 二重ｌｏｘ組換えに基づく真核生物発現ライブラリーおよび使用方法
US20030044398A1 (en) 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP2007535913A (ja) 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
EA014182B1 (ru) 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
US8288109B2 (en) 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
MX2009012526A (es) 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.

Also Published As

Publication number Publication date
MXPA05006724A (es) 2005-09-08
EP1762617A1 (en) 2007-03-14
US9163232B2 (en) 2015-10-20
DE602004002275T2 (de) 2007-09-06
US20090136498A1 (en) 2009-05-28
SI1583830T1 (sl) 2006-12-31
EP1583830A2 (en) 2005-10-12
CA2512647C (en) 2013-10-08
AU2004203727B2 (en) 2008-01-31
WO2004061104A3 (en) 2004-11-04
KR101024443B1 (ko) 2011-03-23
ATE338816T1 (de) 2006-09-15
KR20050101538A (ko) 2005-10-24
ES2273202T3 (es) 2007-05-01
JP2006515520A (ja) 2006-06-01
HK1078896A1 (en) 2006-03-24
AU2004203727A1 (en) 2004-07-22
EP1583830B1 (en) 2006-09-06
NZ541458A (en) 2006-04-28
IL169101A (en) 2009-02-11
EA013225B1 (ru) 2010-04-30
JP2010268806A (ja) 2010-12-02
JP4589914B2 (ja) 2010-12-01
PT1583830E (pt) 2006-11-30
CA2512647A1 (en) 2004-07-22
AU2004203727C1 (en) 2008-08-21
BRPI0406678A (pt) 2005-12-20
WO2004061104A2 (en) 2004-07-22
EA200501101A1 (ru) 2006-02-24
DE602004002275D1 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
DK1583830T3 (da) Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner
EA200700249A1 (ru) Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения
DK2152872T3 (da) Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein
US12024548B2 (en) Rapid method for cloning and expression of cognate antibody variable gene segments
Kurosawa et al. Rapid production of antigen-specific monoclonal antibodies from a variety of animals
CN105602960A (zh) 抗体的快速人源化
JP2015503907A (ja) 真核細胞のための全長抗体提示システムおよびその使用
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
KR20240130125A (ko) 항-gprc5d 항체 및 그의 응용
ATE498013T1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
Price et al. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas
CN118339304A (zh) 克隆的中国仓鼠卵巢细胞及其用途
CN106478773A (zh) 一种人工合成的新型信号肽
US20190031752A1 (en) Method for Producing Antibodies
WO2009086352A2 (en) Cynomolgus toll-like receptor 3
CN120239745A (zh) 永生化细胞的制造方法
MX2024006573A (es) Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.
Lee et al. Increasing hybridoma viability and antibody repertoire after the cell fusion by the use of human plasma as an alternative supplement